A disruptive multi-sensor chip for fast and effective management of Sepsis at the point of Care

Informazioni relative al progetto

SepsiCare

ID dell’accordo di sovvenzione: 888337

DOI

10.3030/888337

Progetto chiuso

Data della firma CE 2 Dicembre 2019

Data di avvio 1 Gennaio 2020

Data di completamento 31 Agosto 2020

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

BIALOOM LTD
Cyprus

Periodic Reporting for period 1 - SepsiCare (A disruptive multi-sensor chip for fast and effective management of Sepsis at the point of Care)

Periodo di rendicontazione: 2020-01-01 al 2020-08-31

Sintesi del contesto e degli obiettivi generali del progetto

The project focuses on the use of novel photonic biosensing technology used to accelerate the diagnosis and treatment of severe bacterial infections next to the patient. The solution relies on a novel photonic integrated biochip that is capable to measure a set of key patient-condition indicators to the clinician from small volumes of patient blood in order to accelerate sepsis diagnosis, monitor disease progression and assess the effects of treatment within minutes. This feasibility study revealed that sepsicare is looking at the right direction and a deeper understanding of the market needs, specifications and challenges had to be implemented. With this study a major market opportunity was verified in point of care diagnostics in the Emergency Room (ER) and Intensive Care Units (ICU) of Hospitals and the project will continue pursuing further development financing.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

In summary the project focused in three main activities.
Task 1 performed a market survey and analysis, end user studies through interviews and communication with key stakeholders, as well as a preliminary review of directives and regulatory requirements.
Task 2 involved a technical feasibility study based on the market analysis results.
Task 3 focused on the generation of an elaborate business plan. The initial business plan was updated to include a detailed marketing, dissemination and commercialization plan, a verified USP, pricing strategies, IPR and a financial plan resulting in the maximum permissible resources to bring the product into the market.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Sepsicare aims to bring a new solution to the market for addressing the global unmet need for fast diagnosis and therapy of acute infections and sepsis with clear socioeconomic impact. More specifically, sepsis affects more than 30 million people worldwide each year translating into healthcare yearly costs nearly $60 billion in the US alone. Starting appropriate and effective antimicrobial treatment is crucial for sepsis survival. Achieving an early and accurate diagnosis is a prerequisite for rapid and successful antibiotic therapy. However, point of care (POC) solutions for fast, affordable and effective management of sepsis remains a challenge. The impact of this unmet clinical need to the hospitals relates to the increased time & cost of patient hospitalization. For patients, this has an impact on increased mortality and morbidity (1 in 3 patients of sepsis die) resulting from suboptimal treatment of bacterial infections.